Royalty Pharma's dividends per share for the
three
months ended in Mar. 2026 was €0.20. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.77. Its Dividend Payout Ratio for the
three
months ended in Mar. 2026 was 0.28. As of today, Royalty Pharma's Dividend Yield % is 1.48%.
Warning Sign:
Royalty Pharma PLC stock Dividend Yield % is close to 5-year low.
During the past 12 months, Royalty Pharma's average Dividends Per Share Growth Rate was 5.30% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 5.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 18.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 9 years, the highest 3-Year average Dividends Per Share Growth Rate of Royalty Pharma was 38.70% per year. The lowest was 5.00% per year. And the median was 7.30% per year.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Royalty Pharma (FRA:RPD) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Royalty Pharma's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as
During the past 9 years, the highest Dividend Payout Ratio of Royalty Pharma was 0.55. The lowest was 0.33. And the median was 0.46.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Royalty Pharma Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.235000
2026-05-15
2026-05-15
2026-06-10
Cash Dividend
quarterly
USD:EUR 0.856000
USD 0.235000
2026-02-20
2026-02-20
2026-03-10
Cash Dividend
quarterly
USD:EUR 0.846000
USD 0.220000
2025-11-14
2025-11-14
2025-12-10
Cash Dividend
quarterly
USD:EUR 0.865000
USD 0.220000
2025-08-15
2025-08-15
2025-09-10
Cash Dividend
quarterly
USD:EUR 0.859000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Royalty Pharma's Dividend Yield (%) for Today is calculated as
Current Share Price is €50.60.
Royalty Pharma's Dividends per Share for the trailing twelve months (TTM) ended in Today is €0.77925.
During the past 9 years, the highest Dividend Yield of Royalty Pharma was 3.34%. The lowest was 0.31%. And the median was 2.12%.
Warning Sign:
Royalty Pharma PLC stock Dividend Yield % is close to 5-year low.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma Dividends per Share Related Terms
Royalty Pharma Dividends per Share Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RPD vs ROIV, MRNA, BNTX: Dividends per Share Comparison
For the Biotechnology subindustry, Royalty Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Dividend Yield % falls into.
Royalty Pharma (FRA:RPD) has a Dividends per Share of €0.77 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Dividends per Share too high?
Royalty Pharma's current Dividends per Share is €0.77. Overall, Royalty Pharma has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Dividends per Share compare to ROIV and MRNA?
Royalty Pharma's Dividends per Share of €0.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Dividends per Share is €0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €33.77, compared to a current price of €50.60 — trading 49.8% above its estimated fair value. The current Dividends per Share is €0.77. Royalty Pharma's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Dividends per Share is €0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (FRA:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €50.60 is trading 49.8% above its estimated GF Value™ of €33.77.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for FRA:RPD:
Dividends per Share: €0.77
GF Value™: €33.77 vs. price of €50.60 (49.8% above fair value)
No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
68GF Score
Get the complete analysis for FRA:RPD
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RPD has been successfully added to your 
